Lymphocytes have a role in protection, but not in pathogenesis, during La Crosse Virus infection in mice by Clayton W. Winkler et al.
RESEARCH Open Access
Lymphocytes have a role in protection, but
not in pathogenesis, during La Crosse Virus
infection in mice
Clayton W. Winkler, Lara M. Myers, Tyson A. Woods, Aaron B. Carmody, Katherine G. Taylor and Karin E. Peterson*
Abstract
Background: La Crosse Virus (LACV) is a primary cause of pediatric viral encephalitis in the USA and can result in
severe clinical outcomes. Almost all cases of LACV encephalitis occur in children 16 years or younger, indicating an
age-related susceptibility. This susceptibility is recapitulated in a mouse model where weanling (3 weeks old or
younger) mice are susceptible to LACV-induced disease, and adults (greater than 6 weeks) are resistant. Disease in
mice and humans is associated with infiltrating leukocytes to the CNS. However, what cell types are infiltrating into
the brain during virus infection and how these cells influence pathogenesis remain unknown.
Methods: In the current study, we analyzed lymphocytes recruited to the CNS during LACV-infection in clinical
mice, using flow cytometry. We analyzed the contribution of these lymphocytes to LACV pathogenesis in weanling
mice using knockout mice or antibody depletion. Additionally, we studied at the potential role of these
lymphocytes in preventing LACV neurological disease in resistant adult mice.
Results: In susceptible weanling mice, disease was associated with infiltrating lymphocytes in the CNS, including NK
cells, CD4 T cells, and CD8 T cells. Surprisingly, depletion of these cells did not impact neurological disease, suggesting
these cells do not contribute to virus-mediated damage. In contrast, in disease-resistant adult animals, depletion of both
CD4 T cells and CD8 T cells or depletion of B cells increased neurological disease, with higher levels of virus in the brain.
Conclusions: Our current results indicate that lymphocytes do not influence neurological disease in young mice, but
they have a critical role protecting adult animals from LACV pathogenesis. Although LACV is an acute virus infection,
these studies indicate that the innate immune response in adults is not sufficient for protection and that components
of the adaptive immune response are necessary to prevent virus from invading the CNS.
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Background
La Crosse Virus (LACV) is a tri-segmented, single-
stranded, negative-sense RNA virus of the genus Orthobu-
nyavirus, in the Bunyaviridae family. The virus is primarily
transmitted by the Eastern Tree Hole mosquito (Ochlero-
tatus triseriatus) and was first shown to cause human
neurological disease when isolated from the brain of a
4-year girl who died from viral encephalitis in La Crosse,
Wisconsin in 1960 [1]. Cases of LACV encephalitis have
been reported in 29 states, and the virus has been found
in other invasive mosquito species, suggesting this is an
emerging disease [2, 3]. LACV is a primary cause of
pediatric viral encephalitis in the USA, with almost all
cases of LACV-induced neurological disease observed in
children under the age of 16. Some of these cases can be
severe, with symptoms such as paralysis or coma and in a
few cases per year, even death. In contrast, in adults and
older teens LACV infection is generally either asymp-
tomatic or causes a mild febrile disease. It does not
cause encephalitis, suggesting that in adults virus is ef-
fectively cleared following infection.
Currently, there is no vaccine available to inhibit
LACV infection [4, 5] or therapy to treat virus-induced
encephalitis [2]. Thus, a better understanding of the
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mediators of viral pathogenesis in the central nervous
system (CNS) as well as the mechanisms by which adults
are protected from the development of encephalitis is
necessary to mitigate disease impact. In patient brain bi-
opsies and animal models of LACV-induced encephal-
itis, a common feature of disease pathology is infiltration
of leukocytes in the brain [6–8]. However, the make-up
of this infiltrating population and their potential role in
LACV pathogenesis remains unknown. We have previously
established that circulating leukocytes do not contribute to
virus neuroinvasion [9] as has been suggested for other en-
cephalitic viruses [10, 11]. However, these cells may have
other roles in influencing viral pathogenesis. Infiltrating
lymphocytes including natural killer (NK) cells, CD8+ T
cells, CD4+ T cells, and B cells are often necessary for viral
clearance from the brain, mediate recovery from multiple
encephalitic virus infections [12–14] and may protect
against LACV-induced neuronal damage. However, these
cells can also contribute to neuronal damage, as observed
with West Nile encephalitis [15–17]. Determining which
cell populations gain access to the CNS during LACV
infection, as well as the influence of these cells on disease,
is essential for developing therapeutics to inhibit this
disease.
The murine model of LACV infection is ideal for
studying neuropathogenesis and disease resistance, as it
recapitulates the age-dependent susceptibility observed
in humans [18, 19]. Following peripheral infection, adult
mice are resistant to neurological disease and have low
CNS titers [19], while weanlings are susceptible and have
high CNS titers [18, 20]. This age-related resistance in
adults appears to be due to the inability of LACV to rep-
licate in the periphery and/or invade the CNS, as admin-
istration of LACV to the CNS by intracerebral [18] or
intranasal inoculation [9] results in neurological disease
in adult mice. Suppression of type I interferon (IFN) sig-
naling in the periphery or depletion of myeloid dendritic
cells (DCs) in adult animals can result in neurological
disease [21, 22], suggesting that an efficient anti-viral
type I IFN response is necessary for preventing disease
in adult animals. However, it remains unknown whether
the innate immune response is sufficient to control LACV
infection in adult animals, or if adaptive immune responses,
including the production of neutralizing antibodies, are also
necessary in preventing the development of neurological
disease.
In the current study, we examined the role of different
lymphocyte populations in mediating neurological disease
following LACV infection in weanling mice. Additionally,
we determined if these lymphocytes influenced viral clear-
ance and protection in adult mice. Lymphocyte-deficient
transgenic mice and depletion studies demonstrated
that lymphocytes did not significantly influence LACV-
induced neurological disease in young animals.
However, both B and T cells were necessary for efficient
virus clearance and the prevention of neurological dis-
ease in adult animals. These findings demonstrate that
while lymphocytes are not mediators of disease in young
susceptible animals, they do provide protection in resist-
ant adult animals. Furthermore, this study indicates that
both innate and adaptive immune responses are essential
for efficient virus clearance and the prevention of neuro-
logical disease following LACV infection.
Methods
Infection of mice with LACV and neurological disease
criteria
All animal studies were conducted using the animal proto-
col RML2014-011, which was approved by the NIH/
NIAID/RML Institutional Animal Care and Use Commit-
tee. Founder wildtype (C57BL/6), Rag1-/-, and μMT-/- mice
on the C57BL/6 background were purchased from Jackson
Laboratories and maintained in a breeding colony at RML.
LACV 1978 stock, a human isolate, was a kind gift from
Richard Bennett (NIAID, NIH) and has been previously
described [8]. Mice at 3 (weanling) or 6–8 (adult) weeks of
age were inoculated with 103 plaque forming units (PFU)
of LACV in phosphate-buffered saline (PBS) intraperitone-
ally (i.p.) in a volume of 200 μl/mouse. Mock infections
consisted of an equal volume of Vero cell culture super-
natant diluted into PBS. Mice were observed daily for
signs of neurological disease that included hunched pos-
ture, seizures, reluctance, or inability to move normally
or paralysis. Animals with clear clinical signs of neuro-
logical disease were scored as clinical and euthanized
immediately.
Treatment of mice with cell-depleting antibodies
For the depletion of T cells, anti-CD8 clone 169.4 and
anti-CD4 clone 191.1 hybridomas were grown in RPMI
media containing 10% FBS to a concentration of 2 mg/
ml as measured by 260/280 absorbance. Supernatants
(gift of Dr. Kim Hasenkrug, NIAID, NIH) were har-
vested and spun at 500 × g for 10 min to remove any cel-
lular debris and then stored at −20 °C until use.
Weanling mice were injected i.p. with 0.5 ml of the
supernatant a total of three times (1, 3, and 5 days post
infection (dpi)). Dual CD8 T cell- and CD4 T cell-
depleted mice received two injections (a total of 1 ml of
supernatant) at each indicated time point. Adult LACV-
infected mice followed the same injection schedule with
two additional injection days at 12 and 19 dpi. Control
mice were injected on the same schedules with 10% FBS
in RPMI. T cell depletion was confirmed by flow cytom-
etry using CD3, CD4, CD8a, and CD8b.2 antibodies.
LACV-infected weanling mice were depleted of natural
killer (NK)-cells by the i.p. administration of 50 μl of
rabbit anti-Asialo-GM1 (Wako) at 1, 3, and 5 dpi. Adult
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LACV-infected mice received the same injections with an
additional injection at 9 dpi. NK cell depletion was
confirmed by flow cytometry using NK1.1 and CD49b
(clone DX5) antibodies.
Evans Blue dye treatment
LACV-infected mice were given Evans Blue dye (200 μl
of 20 mg/ml intravenously) in PBS at 6 dpi, just prior to
the onset of clinical disease. Thirty minutes following dye
infusion, mice were perfused transcardially with 5 ml of
heparinized saline (100 U/ml) and the brains removed and
processed for immunohistochemistry as indicated below.
Dye leakage was visualized using epifluorescence micros-
copy in the TRITC channel.
Tissues processing for flow cytometry
For phenotypic profiling, verification of T cell depletion
studies and lymphocyte activation/proliferation analysis,
whole brains from mock and LACV-infected weanling
mice were isolated at specific time points and a single-
cell suspension made by homogenization and passage
through a 70 μm filter. Individual mice were compared
to allow determination of variation between animals.
Cells were pelleted and resuspended in 70% Percoll/PBS
and underlayed on a 0–30% step Percoll gradient which
was centrifuged at 500g for 20 min at 4 °C. CNS im-
mune cells were recovered at the 30–70% interface,
rinsed in PBS, and placed on ice to await fixing or stain-
ing. For verification of antibody-mediated cell depletions
and lymphocyte-activation/proliferation analysis, the
spleens from weanling and adult mice were homoge-
nized through a 70 μm filter to generate a single-cell
suspension and red blood cells were removed using 2%
dextran T500–PBS and/or lysis buffer (0.15 M NH4Cl,
10 mM KHCO3, 0.1 M EDTA).
Phenotyping CNS-infiltrating immune cells and splenocytes
by flow cytometry
Cells were isolated as described above and then processed
for flow cytometry as previously published [22]. Briefly,
cells were fixed in 2% paraformaldehyde and then perme-
abilized with 0.1% saponin–2% bovine serum albumin
(BSA) in PBS. Fc receptors were blocked using CD16/
CD32 Fcγ III/II (BD Biosciences, clone 2.4G2). Cells were
stained using the following panel of antibodies (all anti-
bodies used for flow cytometry were purchased from BD
Pharmigen, BioLegend, Miltenyi, eBiosciences, or Molecu-
lar Probes) to establish a lymphocyte phenotype: CD45-PE
(30-F11), CD4-APC/Cy7 (GK1.5), CD8a-PB (53-6.7),
CD8b.2-FITC (53-5.8), CD3-PerCP/Cy5.5 (UCHT1),
CD19-PE-CF594 (1D3), NK1.1-AF700 (PK136), and
CD49b (DX5)-PE (DX5). The following antibodies were
used in various combinations with the antibodies from the
lymphocyte panel to exclude non-lymphocytic cells:
CD11c-PE/Cy7 (HL3), pDCA1-APC (JF05-1C2.4.1),
CD11b-APC (M1/70), Ly6G-PB (1A8), Ly6C-AF700
(HK1.4), and F480-BV510 (BM8). All flow cytometry data
was obtained using an LSRII (BD Biosciences) and ana-
lyzed using either FlowJo software (version 10.2; TreeStar,
Inc) or FCS Express software (version 3, De Novo). Live
cells were retained and doublets excluded using SSC-A
and FSC-A gating and then live cells were gated by time
to exclude any artifact caused by erratic sample flow.
Analysis of CNS-infiltrating and splenic lymphocyte
activation and proliferation by flow cytometry
To determine lymphocyte activation and proliferation
state, CNS-infiltrating cells and splenocytes were isolated
as described above and surface labeled for ~30 min at
4 °C. Antibodies used for surface staining were as fol-
lows: Pacific Blue-anti-CD8 (53-6.7) and CD4 (RM4-5),
APC/Cy7-anti-CD3e (17A2), PerCP-Cy5.5-anti-CD43
(1B11), AF488-anti-CD25 (PC61), FITC-anti-CD107a
(1D4B), PE-anti-CD11a (2D7), BV605-anti-KLRG1 (2F1),
PE-CF594-anti-PD1 (J43), and PE-Cy7-anti-CD62L
(MEL-14). Cells were then fixed overnight using re-
agents and following recommendations from the
eBioscience Foxp3 kit, permeabilized, and then stained
intracellularly with APC-anti-Foxp3 (FJK-16s) or APC-
anti-Granzyme B (GRB05) and Alexa700-anti-Ki-67 (B56).
Cells were then washed and fixed for 30 min at 4 °C with
2% paraformaldehyde. Flow cytometry data was collected
as described above. T cells were positively gated by either
CD4+ or CD8+ and CD3+ co-expression, and in the case
of CD4+ T helper cells, Foxp3 exclusion. T cells were fur-
ther analyzed for the expression of the phenotyping
markers listed above. Splenocytes from the naïve wean-
lings and adults (and non-specific Ig or FMO controls
where appropriate) were used to determine gating
placement.
Immunohistochemistry
At the clinical time point (6–7 dpi), some mice were
perfused transcardially with heparin saline (100 U/ml)
followed by 10% neutral buffer formalin. The whole brain
was serially sectioned (5 μm), and sections were blocked
(5% BSA, 0.05% Triton in PBS) at room temperature (rt)
for 1 h. Primary antibodies against CD3 (1:250, Dako),
LACV (1:1000, gifted by Dr. Robert Tesh) and active-
Caspase 3 (1:250, Promega) were applied to sections and
incubated overnight at 4 °C in blocking buffer. Secondary
antibodies were used to label these specific primaries
(donkey anti-rabbit AF488 and goat anti-mouse AF594)
and to visualize IgG leakage (goat anti-mouse AF488) in
the CNS. Secondary antibodies were incubated for 1 h at
rt. Slides were cover slipped with Prolong Gold mounting
media containing DAPI (Molecular Probes) and imaged
using (1) an epifluorescent Nikon Eclipse 55i clinical
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microscope with a Plan Fluor ×40 objective (NA 0.75) to
generate single images (Figs. 1a and 4a, b) or (2) an Aperio
ScanScope FL (fluorescent) slide scanner (Leica Biosys-
tems) with a UPLSAPO ×20 objective (NA 0.75) to gener-
ate composite images (Fig. 4e–h).
Viremia and neutralizing antibody detection
For detection of viremia, serially diluted plasma was
plated directly to Vero cells as described below. For
quantification of neutralizing antibody, serially diluted
plasma was mixed with 102 PFU of LACV in a final vol-
ume of 200 μl in DMEM/2% FBS/1% Pen Strep. The
mixture was incubated for 1 h at 37 °C for
neutralization. After neutralization, the 200 μl mixture
was added to confluent Vero cells in a 24-well plate and
incubated again for 1 h at 37 °C. After incubation,
500 μl of 1.5% carboxymethyl cellulose in MEM was
overlaid onto the cells and the cells were incubated un-
disturbed at 37 °C for 5 days. Cells were then fixed by
adding 10% formaldehyde to each well until full and
allowed to sit for 1 h at room temperature. After fix-
ation, plates were rinsed gently with deionized water and
stained with 0.35% crystal violet for 15 min. Plates were
rinsed and allowed to air dry inverted. Viral titer was
Fig. 1 Lymphocyte infiltration into the CNS following LACV infection of weanling mice. a Brain tissue sections from an LACV-infected mouse at a
clinical time point (7 dpi) was stained for anti-CD3 (first panel, third panel: magenta) and LACV (second panel, third panel: green). b–g Analysis of in-
filtrating cells by flow cytometry. Brain tissue was removed from mock or LACV-infected mice at 1, 3, 5, or 7 dpi and immune cells were isolated,
antibody labeled, and analyzed by flow cytometry as indicated in the “Methods”. Infiltrating cells were gated by CD45 high expression (data not
shown) and then for b CD4 and CD8 expression as well as c CD19 and NK1.1 expression. b, c are representative data from mice at 7 dpi. d–g
Time course analysis of percent (%) infiltrating cell populations including d CD4+ cells, e CD8+ cells, f NK1.1+ cells, and g CD19+ B cells relative to
the total number of live, CD45hi cells. Data are the mean ± SD for three to nine samples per time point for LACV-infected mice and one to three
mice per time point for mock-infected controls. *P value <0.05 as determined by two-way ANOVA with Sidak’s multiple comparison test
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calculated by dividing the number of plaques per given
sample by the plasma dilution factor multiplied by the
volume of each well. Neutralizing antibody titer was de-
termined by the dilution that inhibited at least 50% of
plaque formation when compared to cells infected with
the 102 LACV.
Real-time PCR
Real-time PCR analysis of mRNA expression was com-
pleted as previously described [23]. The primers used in-
clude Gapdh.2-152F (TGCACCACCAACTGCTTAGC),
Gapdh.2-342R (TGGATGCAGGGATGATGTTC), LACVs.
2-552F (ATTCTACCCGCTGACCATTG), and LACVs.2-
650R (GTGAGAGTGCCATAGCGTTG). Primers were
subjected to BLAST analysis (NCBI) to ensure detection of
only the specified gene and were tested on positive controls
to ensure amplification of a single product. Data for
each sample were calculated as the percent difference in
threshold cycle (CT) value (ΔCT =CT for glyceraldehyde-
3-phosphate dehydrogenase [GAPDH] gene −CT for spe-
cified gene). Gene expression was plotted as the percentage
of gene expression relative to that of the GAPDH gene.
Statistical analysis
All statistical analyses were performed using Prism soft-
ware Version 7.01 (GraphPad) and are described in the
figure legends.
Results
Lymphocyte infiltration into the CNS is associated with
areas of LACV infection in weanling mice
Encephalitis associated with LACV infection in both
mice and humans is in part characterized by perivascular
infiltration of leukocytes into the CNS [7, 8], although
the makeup of the infiltrate is not known. Immunohisto-
chemical analysis of brain tissue sections from LACV-
infected weanling mice showed CD3+ T cells in areas of
LACV-infected neurons at the time of clinical disease
Fig. 2 NK cell depletion slightly delays onset of LACV-induced neurological disease in weanling mice. a–c LACV-infected weanling mice were
treated with a rabbit serum or b anti-Asialo GM1 to deplete NK cells as described in the “Methods.” Flow cytometry analysis at 7 dpi was used
to confirm that treatment with b anti-Asialo GM1, but not a rabbit serum resulted in depletion of NK cells as shown by CD49b (DX5) expres-
sion. Experiment 1 included 4–5 mice per group, experiment 2 had 9–10 mice per group, and experiment 3 had 3 mice per group. Statistical
analysis was completed using the Mantel-Cox log-rank test
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Fig. 3 (See legend on next page.)
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(Fig. 1a). To determine lymphocyte subtypes and when
they first entered the CNS, we analyzed cellular infiltrate
in the CNS by flow cytometry at pre- and clinical time
points using a lymphocyte-specific antibody panel de-
scribed in the “Methods”. Although the majority of infil-
trating CD45hi cells in clinical mice were CD11b+
positive myeloid cells (data not shown), CD4+ T cells,
CD8+ T cells, and NK1.1+ lymphocytes were consistently
found in the CNS (Fig. 1b, c). CD8+ and CD4+ T cells
were increased in the CNS relative to mock controls at
the onset (~7 dpi) of LACV-induced neurological dis-
ease (Fig. 1d, e) while CD19+ B cells were not detected
in the CNS at any point during LACV infection
(Fig. 1g). NK1.1+ NK cells were significantly increased in
the CNS at the pre-clinical 5 dpi time point and remained
elevated through to clinical disease (Fig. 1f). Thus,
lymphocyte infiltration of the weanling brain occurs dur-
ing LACV encephalitis and could play a critical role in
neurological disease.
NK cells are minor contributors to LACV-induced patho-
genesis in weanling mice
NK cells were the earliest and most abundant lymphocyte
to infiltrate the CNS during LACV-induced neurological
disease (Fig. 1f). To directly assess the potential role of
these cells in the disease process, NK cells were systemic-
ally depleted in LACV-infected weanling mice using
Asialo-GM1 rabbit antisera. Flow cytometry analysis dem-
onstrated depletion was effective in inhibiting NK cell re-
cruitment to the brain during clinical disease (Fig. 2a, b).
However, depletion of NK cells appeared to have little
to no effect on disease development, with no statistical
difference observed in two experiments (Fig. 2c, experi-
ments 1 and 3) and a small delay of a few days in one
other (Fig. 2c, experiment 2). Thus, NK cells may have
a minor role in promoting LACV-induced neurological
disease but are not essential for viral pathogenesis.
Infiltrating CD4+ and CD8+ T cells are proliferative and
express effector cell markers but do not contribute to
LACV-induced neurological disease
CD4+ and CD8+ T cells have been shown to influence
pathogenesis and virus clearance associated with enceph-
alitic viruses [12, 15, 24–26]. Since both CD4+ and CD8+
T cells were recruited to the CNS during LACV infection,
we examined the activation and proliferation markers of
these cells and compared them to splenocytes from LACV
and mock-infected animals (Fig. 3a, b). There was a higher
percentage of Ki67+, CD43+, and CD11a+ CD4+ Foxp3−
helper T cells in the spleens of LACV-infected mice com-
pared to mock-infected controls (Fig. 3a) consistent with
the induction of a strong CD4+ T cell response in the per-
iphery. There was also a lower percentage of helper T cells
expressing the naïve T cell marker CD62L (Fig. 3a). Ana-
lysis of infiltrating cells in the brain indicated that most
CD4+ T cells had an active phenotype with 50–90% of the
cells positive for Ki67, CD43, and CD11a, while less than
40% of the cells were positive for CD62L (Fig. 3a). Similar
results were observed with CD8+ T cells in regards to pro-
liferation and activation markers, including Ki67 and
CD107a (Fig. 3b). Of particular interest, greater than 65%
of infiltrating CD8+ T cells were positive for Granzyme B
(Fig. 3b), suggesting these cells are capable of cytotoxic ef-
fector function. Similar to CD4+ T cells, the percentage of
CD8+ T cells expressing the naïve T cell marker CD62L
was decreased, correlating with an increase in activated
CD8+ T cells (Fig. 3b). Brains from mock-infected mice had
too few infiltrating T cells to analyze by flow cytometry.
To determine a role for these infiltrating, activated T
cells in viral pathogenesis, we depleted each cell type with
monoclonal antibodies in weanling mice prior to LACV in-
fection. Flow analysis of infiltrating cells in the brain dem-
onstrated efficient depletion of each cell type with their
respective antibodies (Fig. 3c). A slight decrease in CD8+ T
cells in the CNS was observed in anti-CD4-treated mice,
suggesting that CD4 depletion may affect the CD8+ T cell
recruitment to the CNS (Fig. 3c). However, depletion of ei-
ther T cell subtype in weanling mice did not significantly
alter the occurrence or onset of neurological disease fol-
lowing LACV infection (Fig. 3d), suggesting that T
cells are not involved in either the development of
neurological disease or in inhibiting its progression.
IgG antibody is present in the CNS during LACV-induced
neurological disease in weanling mice but does not alter
neurological disease
The lack of detectable B cells in the CNS during disease
could be due in part to isolation methods used or the
(See figure on previous page.)
Fig. 3 CNS-infiltrating T cells are proliferating and activated during LACV infection but do not significantly alter LACV pathogenesis in weanling mice.
Splenocytes and CNS-infiltrating a CD4+, Foxp3− T helper, and b CD8+ CD3+ cytotoxic T cells were analyzed for expression of proliferation and activation
markers by flow cytometry at the clinical time point (6–7 dpi). Data are presented as percent (%) of either CD4+ or CD8+ T cells positive for the
proliferation marker Ki-67, the activation markers CD43, CD11a, GranzymeB, or CD107a or the naïve T cell marker CD62L. c LACV-infected
weanling mice were treated with RPMI/10% FBS (control), anti-CD4 or anti-CD8-depleting monoclonal antibodies as described in the “Methods”. De-
pletions were confirmed by flow cytometry analysis of brain tissue at the clinical time point (5–7 dpi). Data are a summary plot of two independent ex-
periments with 4–12 mice per group. d 18 vehicle control-, 11 anti-CD8-, and 8 anti-CD4-treated mice were followed for the development of clinical
signs of neurological disease. Statistical analysis was completed using the Mantel-Cox log-rank test
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loss of CD19 when B cells become plasma cells. Add-
itionally, even though these cells were not detected in
the brain, they could still be influencing pathogenesis
through actions elicited by soluble immunoglobulin (Ig)
entering the brain [27, 28]. Blood-brain barrier break-
down occurs in areas of LACV infection [9], which may
allow anti-LACV antibodies to enter the CNS. Immuno-
histochemistry for mouse IgG in the CNS was completed
using LACV-infected mice that had received Evans Blue
dye to identify areas of a blood-brain barrier leakage
(Fig. 4a). IgG was found within the brain parenchyma of
these mice but only in areas coinciding with Evans Blue
stain (Fig. 4b). As a neutralizing antibody was observed in
the plasma from LACV-mice as early as 4–5 dpi (Fig. 4c),
the IgG detected in these brains could have the capacity
to neutralize virus and affect disease progression.
To directly determine whether antibody responses were
important for LACV pathogenesis, B cell deficient wean-
ling μMT-/- mice [29] were infected with LACV and
followed for neurological disease. No difference was ob-
served in either clinical disease development (Fig. 4d) or
virus infection in the brain (not shown) in weanling
μMT-/- mice compared to age-matched wildtype controls.
Thus, despite the detection of IgG in the CNS of LACV-
infected mice, the antibody response did not appear to in-
fluence LACV pathogenesis in susceptible weanling mice.
Combined B cell and T cell deficiency does not influence
LACV-induced neurological disease in weanling mice
Despite the fact that B cells (Fig. 4d) and T cells (Fig. 3d)
were not individually necessary for the development of
LACV-induced neurological disease, it remained pos-
sible that the loss of both cellular and humoral adaptive
immune responses could influence the development of
LACV-induced neurological disease. Therefore, weanling
Rag1-/- mice, which are deficient in both mature B and
T cells [30], were infected with LACV and monitored for
neurological symptoms. No difference was observed in
disease onset or occurrence between wildtype and
Rag1-/- mice (Fig. 4d) and virus infection was evident in
all brain regions in both groups of mice as demonstrated
by immunohistochemistry (Fig 4e, f ). Also, cellular
apoptosis was evident in similar regions of the brain in
both wildtype and Rag1-/- mice, suggesting wide-spread
neuronal death and neuropathology (Fig. 4g, h). Collect-
ively, these findings demonstrate that the adaptive immune
response does not appear to play a significant role in media-
ting LACV-induced neurological damage in young mice
despite the presence of lymphocytes within the CNS.
Adaptive immune responses are necessary for peripheral
control of virus infection in adult mice
The lack of a role for lymphocytes in LACV pathogen-
esis within the CNS in young mice does not rule out a
potential role for these cells in controlling peripheral
infection and preventing virus entry to the CNS. Adult
(6–8 weeks) mice are relatively resistant to LACV-induced
neurological disease with less than 25% of wildtype mice
developing clinical signs [22]. Previous studies had identi-
fied a strong role for early type I IFN responses in control-
ling virus replication in adult animals, but the impact of
the adaptive immune response in preventing the develop-
ment of neurological disease in these mice had not been
examined. Infection of adult Rag1-/- mice resulted in the
onset of clinical neurological disease within 10–12 dpi in
100% of infected mice, compared to less than 20% of wild-
type mice (Fig. 5a). This increase in disease was associated
with higher levels of detectable virus in both the brain and
spleen of Rag1-/- mice (Fig. 5b, c). Thus, a functional
lymphocyte response was necessary to control peripheral
virus infection and to prevent development of LACV
encephalitis in disease-resistant adult mice.
Neutralizing antibody producing B cells are essential for
controlling LACV infection
Analysis of wildtype mice indicated the production of
anti-LACV neutralizing antibody occurred in most mice
by 7–10 dpi (Fig. 5d). As expected, uMT-/- and Rag1-/-
mice did not produce neutralizing antibody (Fig. 5d). To
determine whether B cells and neutralizing antibodies
were essential for protection from LACV-induced
neurological disease, we infected μMT-/- mice with 103
(See figure on previous page.)
Fig. 4 Immunoglobulin can be detected in the brain of LACV-infected weanling mice but does not influence the development of neurological
disease or neuropathology. a, b Detection of antibody in the brain by immunohistochemistry of LACV-infected weanling mice at the clinical time
point (6 dpi) that were treated i.p. with Evans Blue dye 1 h prior to tissue removal. Brain tissue sections were analyzed for Evans Blue to detect
vascular leakage (magenta) and either a rat Ig as a negative control or b mouse IgG (green) was used to detect leakage of antibodies into the
brain. c Analysis of plasma from LACV-infected weanling mice at 4–5 dpi for NAb. Data are plotted as the limiting dilution for the inhibition of
virus replication on a log2 scale. Each symbol represents an individual animal. d Weanling wildtype (n = 22), μMT-/- (n = 6), and Rag1-/- (n = 10)
mice develop neurological disease with similar rate and frequency. All mice were 3 weeks of age when infected i.p. with 103 PFU of LACV and followed
for clinical disease. Statistical analysis was completed using the Mantel-Cox log-rank test with no significant difference detected. Representative, adja-
cent sections of brain tissue from e, g LACV-infected weanling wildtype and f, h Rag1-/- mice with neurological disease (6–7 dpi) were stained for LACV
(green) and active-Caspase 3 (white). Higher magnification insets in e and f show infected cells (LACV: green, DAPI: blue) with neuronal morphology
within the hippocampus (red boxes). Insets in g and h demonstrate cells undergoing apoptosis (active-Caspase 3, white) within similar regions of the
midbrain (red boxes) in both genotypes
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PFU of LACV. Most, although not all, μMT-/- mice de-
veloped neurological disease compared to controls indi-
cating B cells are required for efficient control of LACV
infection (Fig. 5a). Susceptibility correlated with detect-
able viral RNA in the brain and the spleen of uMT-/-
mice, which were, comparable to viral RNA levels ob-
served in Rag1-/- mice (Fig. 5b). Thus, humoral immune
responses are necessary for protection against LACV-
induced neurological disease in adult animals.
Both CD4 and CD8 T cells are necessary for neurological
disease resistance
To examine the specific roles of CD4+ T cells and CD8+ T
cells in LACV clearance and prevention of viral encephal-
itis, these cell types were depleted from adult wildtype
mice prior to infection with LACV (Fig. 6a) using mono-
clonal antibodies. Depletion of CD4+ or CD8+ T cells indi-
vidually slightly increased the number of mice that
developed neurological disease (Fig. 6b) compared to
vehicle-treated controls. However, when both CD4+ and
CD8+ cells were depleted, all treated mice developed
neurological disease suggesting these cells act synergistic-
ally to suppress LACV infection (Fig. 6b).
Since CD4+ and CD8+ T cells suppressed neurological
disease in adult mice, we examined these cells for activa-
tion and proliferation markers. Mice were analyzed at
7 dpi, the earliest time point of disease in anti-CD4/anti-
CD8-treated mice (Fig. 6b). In three of eight mice, an in-
crease in CD4+ helper T cells expressing Ki-67, CD43, and
CD11a was observed (Fig. 6c, gray circles). These same
mice had increased percentages of CD8+ T cells expressing
Ki67, Granzyme B, and CD107a and a decrease in expres-
sion of CD62L (Fig. 6d). Thus, LACV infection in adult
mice did not induce a consistently robust CD4+ or CD8+
T cell response by 7 dpi, with only a subset of animals
showing a measurable increase in T cell proliferation and
activation. However, these cells are still essential for pro-
tection as depletion of both cell types resulted in all
Fig. 5 Adult Rag1-/- and μMT-/- mice have increased susceptibility to
LACV infection. a–d Adult (6–8 weeks old) wildtype, Rag1-/-, and
μMT-/- mice were infected with 103 PFU of LACV and examined for
a development of neurological disease, b, c virus RNA levels in the b
brain and c spleen as well as the production of d neutralizing
antibodies. a Data are presented as survival curve analysis of
wildtype (n = 37), Rag1-/- (n = 5), and μMT-/- (n = 12) mice. Statistical
analysis was completed using the Mantel-Cox log-rank test. *** P
<0.01. b, c RNA isolated from wildtype, Rag1-/-, and μMT-/- mice at
10–12 dpi was assayed for LACV RNA by real-time PCR. Data were
analyzed as described in “Methods” and are presented as a ratio of
expression relative to housekeeping gene for each sample. Each
symbol represents an individual mouse. d Neutralizing antibodies
were detected at 5–10 dpi in wildtype mice. Data are presented as
the dilution of plasma resulting in 50% inhibition of virus infection
on a log2 scale. No detectable neutralizing antibodies were ob-
served in Rag1-/- or μMT-/- mice
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animals developing neurological disease (Fig. 6b), suggest-
ing that a more robust response occurs later in infection
or that a modest response is sufficient to clear virus.
NK cells do not contribute to LACV clearance
When activated, NK cells can contribute to viral clear-
ance through a cytotoxic mechanism [31]. To determine
if NK cells contribute to LACV clearance by the
peripheral immune response, adult wildtype mice were
infected with LACV and then treated with NK cell-
depleting Asialo-GM1 or a control antibody (Fig. 7). De-
pletion of NK cells was confirmed using DX5 and NK1.1
markers (Fig. 7a). NK cell-depleted mice were as resist-
ant to the development of LACV-induced neurological
disease as control-treated mice (Fig. 7b) indicating that
NK cells are not essential for protection against LACV
Fig. 6 CD4 and CD8 T cells contribute to protection against LACV-induced disease in adult mice. a, b LACV-infected adult mice were treated with
RPMI/10% FBS as a vehicle control, anti-CD4, or anti-CD8 as described in the “Methods”. a CD4 and CD8 depletion were confirmed by flow cytometry
analysis of splenocytes. b Neurological disease development from vehicle-treated controls (n = 11), anti-CD4-treated (n = 9), anti-CD8-treated (n = 9),
and anti-CD4/anti-CD8-treated (n = 7) mice. Statistical analysis was completed using the Mantel-Cox log-rank test. Although individual anti-CD4 or anti-
CD8-treated mice had slightly increased incidence of neurological disease, only depletion of both subsets resulted in a significant (* P < 0.05) increase
in neurological disease. c CD4+, Foxp3− T helper, and d CD8+ CD3+ cytotoxic T cells from the spleens of adult mice at 7 dpi were analyzed for expres-
sion of proliferation and activation markers by flow cytometry. Data are presented as percent (%) of either CD4+ or CD8+ T cells positive for the prolifer-
ation marker Ki-67, the activation markers CD43, CD11a, GranzymeB, or CD107a or the naïve T cell marker CD62L. Gray circles indicate a group of three
mice that showed consistent activation of CD4 and CD8 T cell responses, while black circles indicate mice that did not have increased responses
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infection. Thus, NK cells did not appear to have a major
role in LACV pathogenesis, either during disease devel-
opment in weanling mice or in protection in adult mice.
Discussion
Anti-viral type I interferon (IFN) signaling is important
for acute virus infections. Our previous studies have
found that weanling mice that produce low levels of type
I IFN do not efficiently control LACV replication early
during peripheral infection and go on to develop neuro-
logical disease. By contrast, disease-resistant adult mice
produce a robust type I IFN response that suppresses
measurable viral RNA out to 4 dpi [22]. However, by
5 dpi, viral RNA is significantly increased in the spleens
of adult mice, suggesting that a low level of viral replica-
tion is taking place [22] and that other mechanisms of
protection are needed. In the current study, we show
that lymphocytes are necessary for efficient control of
peripheral viral infection and the prevention of neuro-
logical disease. In contrast, lymphocytes do not appear
to have a role in weanling mice, either in preventing dis-
ease development or contributing to pathogenesis.
Our current findings demonstrate that LACV infection
is not completely controlled by the type I IFN response
and that the adaptive immune response is necessary,
through both T cell and B cell responses, to inhibit virus
replication and prevent neurological disease. Interest-
ingly, the onset of disease in Rag1-/-, μMT-/-, or anti-
CD4/anti-CD8-treated adult mice generally occurred
after 10 dpi and ranged from 7–20 dpi (Figs. 5 and 6). In
contrast, disease induced in weanling mice (Figs. 3 and
4) or in adult mice with deficient innate immune re-
sponses [22] had a general onset between 5 and 10 days.
This delay in disease onset in Rag1-/-, μMT-/-, or anti-
CD4/anti-CD8-treated adult mice may be due to the
ability of the type I IFN response to suppress early virus
replication for a short time, resulting in a longer time
period for the virus to reach the CNS and induce dam-
age. This low-level prolonged virus replication appears
to be controlled by the development of the adaptive im-
mune response, requiring both neutralizing antibodies
and T cell responses. How long LACV infection can per-
sist in resistant adult mice without the development of
CNS disease and what cell type is infected in the periph-
ery are questions that remain to be addressed more fully
to understand the role of the adaptive immune response
in LACV pathogenesis.
In contrast to the clear role of lymphocytes in protec-
tion against LACV infection in adult animals, there was
no substantial effect of depletion or deficiency in lympho-
cyte function on the development of neurological disease
in weanling mice. This finding was surprising, as infiltrat-
ing lymphocytes influence pathogenesis in several other
cases of viral encephalitis by either clearing infection [15–
17] or exacerbating disease [13, 14]. Furthermore, analysis
of these cells in LACV-infected weanling mice shows a
strong activation phenotype, both in the brain and in the
spleen. This contrasts with the results observed in adult
mice infected with LACV, where CD4+ and CD8+ T cells
are important for protection, but only a subset of mice
had detectable T cell responses at 7 dpi. Thus, the inability
of CD4+ and CD8+ T cells to affect LACV-induced neuro-
logical disease in weanling mice is not due to an inability
of these cells to respond to virus infection. Indeed, the
strong T cell response in weanling mice may be due to the
higher level of virus replication, and resulting viral anti-
gen, in the younger mice compared to the adults.
An unanticipated result of treating adult mice with ve-
hicle control reagents containing normal fetal calf or
rabbit serum was a trend toward increased incidence of
LACV neurological disease (Figs. 6b and 7c). This sug-
gests that heterologous serum elements are in some way
increasing overall viral infection. Possible mechanisms
include enhanced viral replication or infection, prolonged
viral half-life, suppression of host immune response, or
enhanced viral entry into the brain. Little published
Fig. 7 NK cell depletion does not affect susceptibility in adult mice.
a–c LACV-infected adult mice were treated with a rabbit serum or
b anti-Asialo GM1 to deplete NK cells as described in the
“Methods”. Flow cytometry analysis was used to confirm that treat-
ment with b anti-Asialo GM1, but not a rabbit serum resulted in
depletion of NK cells. c NK cell depletion did not significantly affect
development of neurological disease. Data are plotted as a survival
curve analysis of five rabbit serum-treated and six anti-Asialo GM1-
treated mice. Statistical analysis was completed using the Mantel-
Cox log-rank test. No statistical difference was observed
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evidence exists to support the idea that heterologous
serum facilitates viral replication or infection; however,
this possibility cannot be discounted. By contrast, it is
unlikely that serum elements are enhancing viral neu-
roinvasion due to the fact that weanling mice treated
with the same serum-rich reagents did not have faster
disease onset than untreated LACV-infected weanling
mice (Figs. 2 and 3 and [22]). Instead, it is more likely
that injection of mice with a low dose of heterologous
serum is inducing a modest “immunological paralysis”
through a mechanism involving suppression of lympho-
cyte reactivity [32]. This effect, however, is minor as
most control-treated adult mice remain resistant to
LACV neurological disease.
Conclusions
In conclusion, the adaptive immune response, including
the cellular response of CD4+ and CD8+ T cells as well
as the humoral B cell response, does not appear to have
a critical role in LACV-mediated damage in the CNS in
disease-susceptible weanling animals. However, both humoral
and cellular adaptive immune responses are critical for
disease protection in adult animals. It is possible the
more mature and presumptively more efficient adaptive
response [33] in resistant adult animals compared to
susceptible weanling mice is responsible for this disparity
in disease resistance. Furthermore, the adaptive immune
response may be more suited to controlling LACV infec-
tion in a minor cell population in the periphery, rather
than a massive infection of neurons in the CNS. Indeed,
when adult mice are infected either through the intranasal
route or by direct intracranial injection, they develop
neurological disease with similar speed and frequency as
weanling mice despite having a fully developed adaptive
immune response [9, 22]. This insufficiency of response
may be related in part to lymphocyte accessibility to the
brain compared to the peripheral tissues as well as to the
extremely responsiveness of the brain to injury [34]. Thus,
enhancing the peripheral adaptive immune response
against LACV in susceptible individuals may be protective
against the development of neurological disease by clear-
ing infection prior to the virus entering the CNS where in-
fection cannot be efficiently controlled.
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